{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:59:09Z","timestamp":1777449549945,"version":"3.51.4"},"reference-count":31,"publisher":"Impact Journals, LLC","issue":"33","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,8,16]]},"DOI":"10.18632\/oncotarget.10605","type":"journal-article","created":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T09:37:59Z","timestamp":1468575479000},"page":"53116-53126","source":"Crossref","is-referenced-by-count":7,"title":["Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells"],"prefix":"10.18632","volume":"7","author":[{"given":"Seiichi","family":"Okabe","sequence":"first","affiliation":[{"name":"Department of Hematology, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuzo","family":"Tauchi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juri","family":"Sakuta","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Ohyashiki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tokyo Medical University, Tokyo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,7,14]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Cortes","year":"2006","journal-title":"Ann Intern Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Goldman","year":"2002","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hughes","year":"2009","journal-title":"Leukemia"},{"key":"5","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-03-080689","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"6","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia","volume":"26","author":"Deininger","year":"2008","journal-title":"J Clin Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Dong","year":"2010","journal-title":"N Engl J Med"},{"key":"8","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Boqu\u00e9","year":"2010","journal-title":"N Engl J Med"},{"key":"9","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/cncr.28522","article-title":"Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement","volume":"120","author":"Intermesoli","year":"2014","journal-title":"Cancer"},{"key":"10","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Haluska","year":"2012","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1182\/blood-2013-04-494773","article-title":"Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells","volume":"122","author":"Ohyashiki","year":"2013","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.1158\/1078-0432.CCR-11-0396","article-title":"BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment","volume":"17","author":"Hochhaus","year":"2011","journal-title":"Clin Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signaling","volume":"11","author":"Bilanges","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Zhao","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-4-6","article-title":"BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance","volume":"4","author":"Drexler","year":"2011","journal-title":"J Hematol Oncol"},{"key":"16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-015-0165-x","article-title":"Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia","volume":"8","author":"Rai","year":"2015","journal-title":"J Hematol Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1158\/1535-7163.MCT-12-0993-T","article-title":"BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110\u03b1 and p110\u03b4 activities in tumor cell lines and xenograft models","volume":"12","author":"Ziegelbauer","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"18","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1002\/ijc.29579","article-title":"Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells","volume":"137","author":"Krause","year":"2015","journal-title":"Int J Cancer"},{"key":"19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/1538-7445.AM2013-29","article-title":"Abstract 29: Phase I study of intravenous PI3K inhibitor BAY 80-6946 in Japanese subjects","volume":"73","author":"Ohtsu","year":"2013","journal-title":"Cancer Res"},{"key":"20","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjh.12725","article-title":"Advances in understanding the leukemia microenvironment","volume":"164","author":"Konopleva","year":"2014","journal-title":"Br J Haematol"},{"key":"21","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/sj.leu.2403898","article-title":"Compensatory PI3-kinase\/Akt\/mTor activation regulates imatinib resistance development","volume":"19","author":"Neubauer","year":"2005","journal-title":"Leukemia"},{"key":"22","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1038\/cddis.2013.309","article-title":"PI3K\/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor","volume":"4","author":"Belloc","year":"2013","journal-title":"Cell Death Dis"},{"key":"23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/cbt.26725","article-title":"Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation","volume":"15","author":"Ohyashiki","year":"2014","journal-title":"Cancer Biol Ther"},{"key":"24","doi-asserted-by":"crossref","first-page":"e83510","DOI":"10.1371\/journal.pone.0083510","article-title":"Inhibition of PI3K\/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM","volume":"8","author":"Quentmeier","year":"2013","journal-title":"PLoS One"},{"key":"25","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1002\/stem.1748","article-title":"The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors","volume":"32","author":"Holyoake","year":"2014","journal-title":"Stem Cells"},{"key":"26","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Davies","year":"2014","journal-title":"N Engl J Med"},{"key":"27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Ervin","year":"2014","journal-title":"N Engl J Med"},{"key":"28","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-015-0195-4","article-title":"Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19\/CD3 for refractory acute lymphoid leukemia","volume":"8","author":"Liu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-015-0224-3","article-title":"ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development","volume":"8","author":"Liu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"30","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","article-title":"NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia","volume":"106","author":"Wakayama","year":"2005","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"e89080","DOI":"10.1371\/journal.pone.0089080","article-title":"Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia","volume":"9","author":"Ohyashiki","year":"2014","journal-title":"PLoS One"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T03:49:53Z","timestamp":1656820193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,14]]},"references-count":31,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2016,8,16]]}},"alternative-id":["10605","27437766"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10605","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,14]]}}}